SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
SMMT reported Third Quarter ended September 30, 2026 results. The stock moved -12.2% on the print.
SMMTearnings

Earnings reactions, page 7

Summit Therapeutics Inc. (SMMT) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP operating expenses were $214.6 million for the third quarter of 2026, compared to $234.2 million for the same period of the prior year.
  • Non-GAAP operating expenses were $166.9 million for the third quarter of 2026, compared to $103.4 million for the same period of the prior year.
  • GAAP R&D expenses were $169.1 million for the third quarter of 2026, compared to $131.1 million for the same period of the prior year.
  • Non-GAAP R&D expenses were $145.2 million for the third quarter of 2026, compared to $90.5 million for the same period of the prior year.
  • GAAP net loss in the third quarter of 2026 was $208.4 million, or $(0.26) per basic and diluted share.
  • Non-GAAP net loss in the third quarter of 2026 was $160.7 million, or $(0.20) per basic and diluted share.

Notes

The company notes that GAAP financial measures are adjusted for stock-based compensation to arrive at non-GAAP financial measures.

Price and volatility reaction

The stock moved -12.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +23.0 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release16.172026-11-04
Close after release14.192026-11-05
Realised move-12.2%close to close
30d ATM IV change+23.0 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →